Estimates of the combined ICUR and the economic value to society (defined as monetized cumulative net quality-adjusted life years-QALYs-gained minus net treatment costs) created over the product life cycle are based on projections of the annual disease incidence of HER2+ ABC and MBC from launch in 1998 through patent expiry and projected ICURs in MBC and in ABC over this period. Model assumes a U.S. perspective and lifetime horizon for the CU models. All cost and outcomes are discounted at 3% to 1998. RESULTS: We project that in 2016 the volume of ABC treatment with H will be approximately 3 to 4 times that of MBC. For MBC, the estimated ICUR is $95,500 (mean gain = 0.5 QALYs); for ABC, the estimate is an ICUR of $26,417 (mean gain = 1.7 QALYs). Over the product life cycle, the overall ICUR is $34,400 per QALY with a total of 465,000 discounted QALYs gained. If these QALYs were valued at $50,000 or $150,000, the projected economic value of H treatment would range from $23 to $70 billion, respectively. CONCLUSIONS: Using the case of trastuzumab, we show how the addition of the ABC indication and the product life cycle approach affects the overall economic impact. The indication-specific models used typically do not account for the important interdependence of drug development and adoption decisions over the life cycle. This raises an important policy question about the meaning of the "societal perspective" for drugs with multiple indications.
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Jagiellonian University, Cracow, Malopolska, Poland, 2 Jagiellonian University, Cracow, Poland OBJECTIVES: Modeling techniques are widely used in pharmacoeconomics studies. Computational intelligence (CI) is an example of modeling approach successfully applied in various areas of science and technology. The aim of the study was to assess the usefulness of CI tools in pharmacoeconomics analysis. METHODS: Database contained 100 patients with Non-small Cell Lung Cancer (NSCLC) in IIIB and IVth stage. Every patient was described by 30 features (pharmacotherapy and diagnostics path). The pharmacotherapy characteristics included chemotherapy schemes based on cisplatin or carboplatin with vinorelbine, gemcitabine, etoposide and the additive therapy. The output value had binary characteristic (35 weeks of survival as a threshold). Data Mining Software WEKA was used. Support vector classifier (SMO), naive Bayes classifier (NB), and decision trees (RandomForest, J48) were applied. The quality of models was assessed based on their generalization abilities. The 10-fold cross validation procedure was applied. RESULTS: The best results obtained for each one of above mentioned tools were as follows: SMO-80% of all positive, 70% of good positive and 86% of good negative; NB-69%, 70%, 68%; RandomForest-75%, 68%, 79%; J48-74%, 57%, 84% respectively. Using best obtained models, the in silico tests with various chemotherapy schemes were applied. Simultaneously, the cost-effectiveness studies with modeled survival were performed as the effectiveness measure of simulated in silico chemotherapeutic schemes. The results confirm the literature information about the clinical and economical efficacy of abovementioned chemotherapy schemes (i.e. no statistical significance in clinical outputs between vinorelbine-cis-platine and gemcitabine-cis-platine but the vinorelbine based scheme was more cost-effective). The experiment with in silico cytostatics dose reduction from 100% to 0 showed that BSC therapy could be the valuable alternative for palliative chemotherapy. CONCLUSIONS: Computational intelligence was found to be powerful and flexible tool allowing reliable models creation to perform in silico search for optimal therapy. (Olsen JH, 2005) . A literature review revealed a paucity of Quality of Life research in this area with no published utility values. The objective of this study was to collect utility values for active disease and remission health states for use in a health economic model. METHODS: Patients with follicular lymphoma (n = 222) were recruited from 8 sites around the UK. Utility scores were obtained using the EQ-5D questionnaire. Patients were analysed according to 5 health states (newly diagnosed, relapsed, partial response to treatment, full response to treatment/remission, and disease-free). These categories were grouped to form two broader health states; firstly "progressionfree" which included patients experiencing partial or full response to treatment and those categorised as disease-free; and secondly "progression" which included relapsed patients.
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RESULTS:
The results of this study show that the utility score of an individual with follicular lymphoma differs according to his or her disease state. The patients with the highest utility scores were those who had experienced a full response to treatment or who were categorised as "disease-free". Those patients who had the lowest utility were those who were categorised as relapsed. Those patients who fell between these two groups were those who were categorised as having partially responded to treatment. CONCLUSIONS: Differences in utility were apparent between patients in the 5 health states. These differences were particularly highlighted when scores were grouped according to "progression-free" and "progression" health states.
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